EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection

Apichart So-Ngern, Naphol Osaithai, Atibordee Meesing, Worawat Chumpangern

Drug Target Insights · 30.10.2023 · 17 · 120-125

DOI: 10.33393/dti.2023.2622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Target Insights, online erschienen am 30.10.2023. Verfasst von Apichart So-Ngern und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Sleep Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenem-resistant Enterobacteriaceae (CRE) is a serious pathogen with high mortality. Recognition of factors associated with mortality and treating these modifiable factors are crucial to reducing mortality.

Objective

To determine the 30-day mortality and factors associated with a 30-day mortality of CRE infection.

Methods

A retrospective cohort study was conducted between January 1, 2015, and December 31, 2019. All patients diagnosed with CRE infection aged ≥18 years were included. Multivariate logistic regression was used for evaluating the factors associated with 30-day mortality and presented as adjusted odds ratio (aOR) with 95% confidence interval (CI).

Result

One hundred and ninety-four patients were enrolled. The 30-day mortality occurred in 75 patients (38.7%). The common antibiotic regimen was monotherapy and combination of carbapenem, colistin, amikacin, tigecycline, and fosfomycin. CRE isolates were susceptible to tigecycline (93.8%), colistin (91.8%), fosfomycin (89.2%), and amikacin (89.2%). The independent factors associated with 30-day mortality were an increasing simplified acute physiology (SAP) II score (aOR 1.11, 95% CI 1.05-1.16, p < 0.001), sepsis at time of CRE infection diagnosis (aOR 7.93, 95% CI 2.21-28.51, p = 0.002), pneumonia (aOR 4.48, 95% CI 1.61-12.44, p = 0.004), monotherapy (aOR 4.69, 95% CI 1.71-12.85, p = 0.003), and improper empiric antibiotic (aOR 5.13, 95% CI 1.83-14.40, p = 0.002).

Conclusion

The overall 30-day mortality of CRE infection was high. The factors associated with mortality were an increasing SAP II score, sepsis at time of CRE infection diagnosis, pneumonia, monotherapy, and improper empiric antibiotic. The study suggested that proper empiric antibiotic and combination antibiotics might reduce mortality from CRE infection.

Autor:innen und Institutionen

  • Division of Sleep Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand.
  • Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand.
  • Division of Infectious Diseases and Tropical Medicines, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand.
  • Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen - Thailand.
  • Division of Pulmonary Medicine and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand.

Zitieren

APA

So-Ngern, A., Osaithai, N., Meesing, A., & Chumpangern, W. (2023). Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection. Drug Target Insights, 17, 120-125. https://doi.org/10.33393/dti.2023.2622

Vancouver

So-Ngern A, Osaithai N, Meesing A, Chumpangern W. Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection. Drug Target Insights. 2023;17:120-125. doi:10.33393/dti.2023.2622

BibTeX
@article{SoNgern2023,
  author = {So-Ngern, Apichart and Osaithai, Naphol and Meesing, Atibordee and Chumpangern, Worawat},
  title = {Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection},
  journal = {Drug Target Insights},
  year = {2023},
  volume = {17},
  pages = {120--125},
  doi = {10.33393/dti.2023.2622}
}
Kostenlos starten →